GoldenGolden
Glycostem

Glycostem

Glycostem is a biotechnology developing cellular immunotherapies.

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

November 20, 2020
Glycostem Therapeutics announces the opening of a phase I/IIa trial for its lead product oNKord® for the treatment of AML patients.
2007
Glycostem was founded.

People

Name
Role
LinkedIn

Hareth Nahi

CMO

Jan Spanholtz

CSO

Troels Jordansen

CEO

Volker Huppert

COO

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Glycostem Therapeutics
December 15, 2020
www.prnewswire.com:443
/PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK)...
Glycostem Therapeutics
November 20, 2020
www.prnewswire.com:443
/PRNewswire/ -- Glycostem Therapeutics B.V., a leading clinical-stage company focused on the development of therapeutic off-the-shelf Natural Killer (NK)...

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.